Table 2.

TNMB (tumor, node, metastasis, blood) classification for patients with mycosis fungoides and Sézary syndrome.

T (skin) 
    T1 limited patch/plaque (<10% of BSA) 
    T2 generalized patch/plaque (>10% of BSA) 
    T3 tumors 
    T4 generalized erythroderma 
N (nodes) 
    N0 no clinically abnormal peripheral lymph nodes 
    N1 clinically abnormal peripheral lymph nodes 
    NP0 biopsy performed, not CTCL 
    NP1 biopsy performed, CTCL 
    LN0 uninvolved 
    LN1 reactive lymph node 
    LN2 dermatopathic node, small clusters of convoluted cells (< 6 cells per cluster) 
    LN3* dermatopathic node, large clusters of convoluted cells (> 6 cells per cluster) 
    LN4* lymph node effacement 
M (viscera) 
    M0 no visceral metastasis 
    M1 visceral metastasis 
B (blood) 
    B0 atypical circulating cells not present (<5%) 
    B1 atypical circulating cells present (>5%) 
T (skin) 
    T1 limited patch/plaque (<10% of BSA) 
    T2 generalized patch/plaque (>10% of BSA) 
    T3 tumors 
    T4 generalized erythroderma 
N (nodes) 
    N0 no clinically abnormal peripheral lymph nodes 
    N1 clinically abnormal peripheral lymph nodes 
    NP0 biopsy performed, not CTCL 
    NP1 biopsy performed, CTCL 
    LN0 uninvolved 
    LN1 reactive lymph node 
    LN2 dermatopathic node, small clusters of convoluted cells (< 6 cells per cluster) 
    LN3* dermatopathic node, large clusters of convoluted cells (> 6 cells per cluster) 
    LN4* lymph node effacement 
M (viscera) 
    M0 no visceral metastasis 
    M1 visceral metastasis 
B (blood) 
    B0 atypical circulating cells not present (<5%) 
    B1 atypical circulating cells present (>5%) 
Close Modal

or Create an Account

Close Modal
Close Modal